Literature DB >> 8453453

Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up.

B Runmarker1, O Andersen.   

Abstract

An incidence cohort consisting of 308 multiple sclerosis patients was followed up repeatedly during at least 25 years of disease. A number of clinical factors were analysed with respect to their validity in assessing the long-term prognosis. Of the onset characteristics, the type of course was the most important, with primary progressive patients experiencing a much more severe course. In patients with an acute onset, low onset age, high degree of remission at first exacerbation, symptoms from afferent nerve fibres and onset symptoms from only one region (as compared with polyregional symptoms) of the central nervous system, were factors significantly associated with a favourable long-term prognosis. Of factors known 5 years after onset, a low number of affected neurological systems, a low neurological deficit score and a high degree of remission from the last bout were the most important favourable prognostic factors.

Entities:  

Mesh:

Year:  1993        PMID: 8453453     DOI: 10.1093/brain/116.1.117

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  104 in total

Review 1.  Physicians, subsequence and consequence.

Authors:  W I McDonald
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-09       Impact factor: 10.154

2.  Relapses and disability accumulation in progressive multiple sclerosis.

Authors:  M Mateo Paz Soldán; Martina Novotna; Nuhad Abou Zeid; Nilufer Kale; Melih Tutuncu; Daniel J Crusan; Elizabeth J Atkinson; Aksel Siva; B Mark Keegan; Istvan Pirko; Sean J Pittock; Claudia F Lucchinetti; Brian G Weinshenker; Moses Rodriguez; Orhun H Kantarci
Journal:  Neurology       Date:  2014-11-14       Impact factor: 9.910

Review 3.  Progressive multifocal leukoencephalopathy and multiple sclerosis: lessons from natalizumab.

Authors:  Annette Langer-Gould; Lawrence Steinman
Journal:  Curr Neurol Neurosci Rep       Date:  2006-05       Impact factor: 5.081

4.  Clinical characteristics of multiple sclerosis in Västerbotten County in northern Sweden.

Authors:  P Sundström; A Svenningsson; L Nyström; L Forsgren
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

Review 5.  Benign multiple sclerosis: does it exist?

Authors:  Jorge Correale; María C Ysrraelit; Marcela P Fiol
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

6.  Isolated optic neuritis and its prognosis for multiple sclerosis: a clinical and paraclinical study with evoked potentials. CSF examination and brain MRI.

Authors:  A Ghezzi; V Torri; M Zaffaroni
Journal:  Ital J Neurol Sci       Date:  1996-10

7.  Treating relapsing multiple sclerosis with subcutaneous versus intramuscular interferon-beta-1a: modelling the clinical and economic implications.

Authors:  Shien Guo; Duygu Bozkaya; Alexandra Ward; Judith A O'Brien; Khajak Ishak; Randy Bennett; Ahmad Al-Sabbagh; Dennis M Meletiche
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

8.  Multiple sclerosis with a progressive course from onset in Lorraine-Eastern France.

Authors:  M Debouverie; S Louis; S Pittion-Vouyovitch; T Roederer; H Vespignani
Journal:  J Neurol       Date:  2007-06-25       Impact factor: 4.849

9.  Quantitative risk-benefit analysis of natalizumab.

Authors:  J P Thompson; K Noyes; E R Dorsey; S R Schwid; R G Holloway
Journal:  Neurology       Date:  2008-07-29       Impact factor: 9.910

10.  Analysis of 45 candidate genes for disease modifying activity in multiple sclerosis.

Authors:  Sreeram V Ramagopalan; Gabriele C Deluca; Katie M Morrison; Blanca M Herrera; David A Dyment; Matthew R Lincoln; Sarah-Michelle Orton; Michael J Chao; Alexandra Degenhardt; Maura Pugliatti; A Dessa Sadovnick; Stefano Sotgiu; George C Ebers
Journal:  J Neurol       Date:  2008-06-20       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.